blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3387019

EP3387019 - RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.08.2022
Database last updated on 26.03.2026
FormerThe patent has been granted
Status updated on  17.09.2021
FormerGrant of patent is intended
Status updated on  02.05.2021
FormerExamination is in progress
Status updated on  14.02.2020
FormerRequest for examination was made
Status updated on  14.09.2018
FormerThe international publication has been made
Status updated on  16.06.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037 / US
[2021/38]
Former [2018/42]For all designated states
The California Institute for Biomedical Research
11119 North Torrey Pines Road
Suite 100
La Jolla, CA 92037 / US
Inventor(s)01 / WANG, Feng
Chinese Academy of Sciences
15 Datun Road
Chaoyang District Beijing, 100101 / CN
02 / LIU, Yan
10717 Calle Mar De Mariposa
San Diego, CA 92130 / US
03 / WANG, Ying
3871 Camino Lindo
San Diego, California 92122 / US
04 / FU, Guangsen
9525 Genesee Avenue
Apt. 206
San Diego, California 92121 / US
05 / SCHULTZ, Peter G.
1650 La Jolla Rancho Road
La Jolla, California 92037 / US
 [2018/42]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2021/42]
Former [2018/42]Marshall, Cameron John
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date16873899.509.12.2016
[2018/42]
WO2016US65779
Priority number, dateUS201562265344P09.12.2015         Original published format: US 201562265344 P
[2018/42]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2017100540
Date:15.06.2017
Language:EN
[2017/24]
Type: A2 Application without search report 
No.:EP3387019
Date:17.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 15.06.2017 takes the place of the publication of the European patent application.
[2018/42]
Type: B1 Patent specification 
No.:EP3387019
Date:20.10.2021
Language:EN
[2021/42]
Search report(s)International search report - published on:US20.07.2017
(Supplementary) European search report - dispatched on:EP18.03.2019
ClassificationIPC:C07K16/46, A61K39/395, A61P35/00, C12N15/09, C07K16/10, C07K14/64, A61P11/00, A61P13/12
[2021/14]
CPC:
C07K14/64 (EP,US); A61K9/0019 (US); A61K9/0048 (US);
A61K9/02 (US); A61K9/10 (US); A61P11/00 (EP,US);
A61P13/12 (EP,US); A61P35/00 (EP); C07K16/11 (EP,US);
A61K2039/505 (US); A61K2039/54 (US); A61K2039/545 (US);
A61K38/00 (US); C07K2317/24 (US); C07K2317/52 (EP,US);
C07K2317/565 (EP,US); C07K2317/732 (US); C07K2317/76 (US);
C07K2317/92 (EP,US); C07K2317/94 (US); C07K2319/00 (EP,US);
C07K2319/30 (US) (-)
Former IPC [2019/16]C07K16/46, A61K39/395, A61P35/00, C12N15/09, C07K16/10, C07K14/64
Former IPC [2018/42]C07K16/46, A61K39/395, A61P35/00, C12N15/09
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/42]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:RELAXIN-IMMUNGLOBULIN-FUSIONSPROTEINE UND VERFAHREN ZUR VERWENDUNG[2018/42]
English:RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE[2018/42]
French:PROTÉINES DE FUSION D'IMMUNOGLOBULINE DE RELAXINE ET PROCÉDÉS D'UTILISATION[2018/42]
Entry into regional phase06.07.2018National basic fee paid 
06.07.2018Search fee paid 
06.07.2018Designation fee(s) paid 
06.07.2018Examination fee paid 
Examination procedure06.07.2018Examination requested  [2018/42]
06.07.2018Date on which the examining division has become responsible
14.10.2019Amendment by applicant (claims and/or description)
18.02.2020Despatch of a communication from the examining division (Time limit: M04)
29.06.2020Reply to a communication from the examining division
04.03.2021Cancellation of oral proceeding that was planned for 24.03.2021
24.03.2021Date of oral proceedings (cancelled)
03.05.2021Communication of intention to grant the patent
10.09.2021Fee for grant paid
10.09.2021Fee for publishing/printing paid
10.09.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21203381.5  / EP4011919
Opposition(s)21.07.2022No opposition filed within time limit [2022/39]
Fees paidRenewal fee
06.07.2018Renewal fee patent year 03
13.12.2019Renewal fee patent year 04
14.12.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.12.2016
AL20.10.2021
CY20.10.2021
EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
MK20.10.2021
MT20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SI20.10.2021
SK20.10.2021
SM20.10.2021
TR20.10.2021
BG20.01.2022
IS20.02.2022
[2024/41]
Former [2024/29]HU09.12.2016
AL20.10.2021
CY20.10.2021
EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
MK20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SI20.10.2021
SK20.10.2021
SM20.10.2021
TR20.10.2021
BG20.01.2022
IS20.02.2022
Former [2024/22]HU09.12.2016
AL20.10.2021
CY20.10.2021
EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
MK20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SI20.10.2021
SK20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2023/30]HU09.12.2016
AL20.10.2021
CY20.10.2021
EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SI20.10.2021
SK20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2023/29]HU09.12.2016
AL20.10.2021
EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SI20.10.2021
SK20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2023/01]AL20.10.2021
EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SI20.10.2021
SK20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2022/49]AL20.10.2021
EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SK20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2022/35]EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SK20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2022/34]EE20.10.2021
HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
PL20.10.2021
RO20.10.2021
RS20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2022/33]HR20.10.2021
LT20.10.2021
LV20.10.2021
MC20.10.2021
PL20.10.2021
RS20.10.2021
SM20.10.2021
BG20.01.2022
IS20.02.2022
Former [2022/24]HR20.10.2021
LT20.10.2021
LV20.10.2021
PL20.10.2021
RS20.10.2021
BG20.01.2022
IS20.02.2022
Former [2022/23]HR20.10.2021
LT20.10.2021
LV20.10.2021
PL20.10.2021
RS20.10.2021
BG20.01.2022
Former [2022/22]LT20.10.2021
RS20.10.2021
BG20.01.2022
Former [2022/21]RS20.10.2021
BG20.01.2022
Former [2022/19]BG20.01.2022
Documents cited:Search[I] WO2015006744  (CALIFORNIA INST BIOMEDICAL RES et al.) [I] 1-15 * table 7, pages 152-153;; claim - * * the whole document *
 [I] WO0243660  (MEDIUMMUNE INC et al.) [I] 1-15 * page 1, claims, SEQ ID NO: 10, Table 2, p. 49; table 3), in SEQ ID NO: 3, 12; page 1; claim - * * the whole document *
 [I] WO0164751  (MEDIMMUNE INC et al.) [I] 1-15 * the whole document * * claim -; sequences 31-33 *
 [A] US2006159695  (DELVECCHIO ALFRED et al.) [A] 1-15 * the whole document *
 [E] WO2018013483  (THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RES et al.) [E] 1-15 * claims 270-274, [004], [0036], [0012], p. 84; claim 209; page 84; claim -; tables 5, 9; sequences 101-114 *
 [I]   WU ET AL: "Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 368, no. 3, 6 April 2007 (2007-04-06), pages 652 - 665, XP022020027, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2007.02.024 [I] 1-15 * the whole document * * figures 1, 6 *

DOI:   http://dx.doi.org/10.1016/j.jmb.2007.02.024
 [I]   WU H ET AL: "Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization", JOURNAL OF MOLECULAR BIO, ACADEMIC PRESS, UNITED KINGDOM, vol. 350, no. 1, 11 May 2005 (2005-05-11) - 1 July 2005 (2005-07-01), pages 126 - 144, XP004918535, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2005.04.049 [I] 1-15 * the whole document * * p. 141, col. 1; abstract, discussion, Fig. 1, 2, Tables 1, 2 *

DOI:   http://dx.doi.org/10.1016/j.jmb.2005.04.049
International search[Y] WO2015006744  (CALIFORNIA INST BIOMEDICAL RES et al.) [Y] 18-19, 20/18-19, 21/20/18-19, 24/18-19, 25/24/18-19, 27-28 * ; abstract; paragraphs [0011], [00256], [00346]-[00348], [00353], [00382], [00518] *
 [Y] US2007293485  (LIM JOHN et al.) [Y] 18-19, 20/18-19, 21/20/18-19, 24/18-19, 25/24/18-19 * ; paragraph [0006]; claim 1 *
 [Y] US2006257918  (RAMANATHAN CHANDRA S et al.) [Y] 27-28 * ; paragraph [0633] *
 [A] US2014187491  (WILMEN ANDREAS et al.) [A] 1-2, 3/1-2 * ; abstract *
 [A] US2002164326  (YOUNG JAMES F et al.) [A] 1-2, 3/1-2 * ; paragraph [0122]; Table 1 *
by applicantWO2015006744
 WO0243660
 AU2012211451
 US6685940
 US6566329
 US6372716
 WO9315722
 US3773919
 EP0133988
 WO9420069
   WU ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 368, no. 3, 6 April 2007 (2007-04-06), pages 652 - 665
   WU ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 350, 1 July 2005 (2005-07-01), pages 126 - 144
   KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
   PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
   ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
   "Additional pharmaceutical agents are set forth in Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY
   "Remington's Pharmaceutical Science", 1980
   SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556
   LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
   LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
   EPPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 - 92
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.